The TRIBE trial compared the FOLFOXIRI regimen plus bevacizumab with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. FOLFOXIRI plus bevacizumab is an acceptable therapeutic option, but the results of the TRIBE trial do not establish this regimen as the best treatment option for patients with metastatic colorectal cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350810 | PMC |
| http://dx.doi.org/10.1634/theoncologist.2014-0495 | DOI Listing |
Publication Analysis
Top Keywords
metastatic colorectal
12
folfoxiri bevacizumab
8
tribe trial
8
patients metastatic
8
colorectal cancer
8
bevacizumab standard
4
standard first-line
4
first-line therapy
4
therapy metastatic
4
colorectal cancer?
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!